Reduced cerebral blood flow in boys with Duchenne muscular dystrophy

Nathalie Doorenweerd1,2, Eve M Dumas2, Eidrees Ghari3,4, Sophie Schmid1,5, Chiara S.M. Straathof6, Pietro Spitali7, Ieke Ginjaar8, Beatris H Wokke9, Debby G.M. Schrans6, Janneke C van den Bergen2, Erik W van Zweel3, Andrew G Webb1, Mark A van Buchem1, Mathias J.P. van Osch1,4, Jan J.G.M. Verschuuren, Jos G.M. Hendriksen6,8, Erik H Niks2, and Hermien E Kan1,3

1Department of Radiology, C.J. Gorter Center for High Field MRI, Leiden University Medical Center, Leiden, Zuid Holland, Netherlands, 2Department of Neurology, Leiden University Medical Center, Leiden, Zuid Holland, Netherlands, 3Leiden Institute for Brain and Cognition, Leiden, Zuid Holland, Netherlands, 4Department of Human Genetics, Leiden University Medical Center, Leiden, Zuid Holland, Netherlands, 5Department of Clinical Genetics, Leiden University Medical Center, Leiden, Zuid Holland, Netherlands, 6Department of Neurological Learning Disabilities, Kempenhaeghe Epilepsy Center, Heeze, Noord-Brabant, Netherlands, 7Department of Medical Statistics, Leiden University Medical Center, Leiden, Zuid Holland, Netherlands, 8Department of Neurology, Maastricht University Medical Center, Limburg, Netherlands

Target audience: Researchers and physicians in the field of neuroscience and neuromuscular diseases, as this research shows the cerebrovascular involvement of a neuromuscular disorder.

Background and purpose: Duchenne muscular dystrophy (DMD) is a neuromuscular disorder known to be associated with specific learning and behavioral disabilities. It is caused by DMD gene mutations leading to absence of the dystrophin protein in various cell types including neurons, astrocytes, vascular endothelial and smooth muscle cells. The role of dystrophin in the central nervous system is not completely understood, and the pathophysiology of the learning and behavioral problems remains elusive. We previously reported reduced grey matter (GM) volume and altered white matter microstructure in DMD compared with healthy age-matched controls. As dystrophin is associated with vasculature as well, we now aimed to assess whether there are changes in cerebral blood flow (CBF) in these DMD patients.

Methods: T1-weighted (TE/TR 4.6 ms/9.8 ms, res 1x1x1 mm) and pseudo-continuous arterial spin labeling (pCASL) (TE/TR 14 ms/4020 ms, post-label delay 1.525 ms, label duration 1650 ms, background suppression pulses (BGS) at 1680 and 2760ms, voxel-size 3x3x3 mm) scans were obtained at 3T from 30 DMD patients and 22 age-matched controls (8-18 years). A customized analysis pipeline was employed that included subtraction of label and control conditions and registration of the CBF maps to T1 and MNI space (FSLv5). Quantification of CBF was performed as described before, slightly adapted to correct for the finite labeling duration (T1 of blood 1664 ms, T2 of arterial blood 50ms, r 1.05 g/mL, labeling efficiency 0.85 and loss of label due to BGS 0.83). Quantification was performed on the mean GM CBF signal and on the CBF maps. Group statistics were performed using a T-test and AVONA for the mean GM CBF; voxel-based group analyses were performed with a GLM and age as covariate.

Results: Representative perfusion maps are shown in figure 1A. DMD patients had lower CBF at 41.1 mL/100g/min +/- 7.8 versus 49.9 +/- 8.7 in controls (p=0.002) (Fig 1B). The reduced CBF was found throughout the brain irrespective of age. The differences remained significant after correcting for grey matter volume, which was also reduced in these patients. The biggest difference with controls was found in the regions involved with neurobehavioral disabilities. A region of interest analysis of the GM CBF revealed significantly lower CBF in the regions involved in neurobehavioral disabilities (p<0.05).

Discussion and conclusions: Boys with DMD have a 17.6% reduced cerebral blood flow compared to age-matched controls. Patients predicted to miss both full length dystrophin and Dp140 isoforms of dystrophin (DMD_Dp140+) also had reduced CBF but to a lesser extent (fig. 1C top).

Figure 1. A) Representative cerebral blood flow maps of a healthy 10y old control (top) and a 9y old boy with DMD (bottom). Color coded values are in ml/min/100g. B) The quantified CBF showing significant CBF reduction in the whole patient group versus controls (left) and in DMD_Dp140- versus controls specifically (right). C) Localization of the reduced perfusion in statistical maps ranging from p<0.05 (red) to p<0.001 (yellow) showing differences throughout the grey matter in both DMD_Dp140+ and DMD_Dp140 versus controls.